Dr Reddy to sell, assign US dermatology brands rights to Encore Dermatology

Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO®(betamethasone dipropionate) Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB®Topical Cream and TRIANEX®0.05% (Triamcinolone Acetonide Ointment, USP) in the United States, to Encore Dermatology.

Under the terms of the agreement, Promius Pharma is eligible to receive an upfront payment and future milestone payments contingent upon achievement of certain commercial objectives.

“This is in line with our renewed strategy to enable us achieve self-sustainability and profitable growth for each of our businesses,” said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy’s.

https://www.marketscreener.com/DR-REDDY-S-LABORATORIES-9058869/news/Dr-Reddy-Laboratories-announces-the-sale-and-assignment-of-the-US-rights-for-its-marketed-dermat-28341990/